Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gisella Volpe

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Letters|July 26, 2008
Imatinib resistance in CMLGisella Volpe, Cristina Panuzzo, Stefano Ulisciani, et al.
Journal of Thrombosis and Thrombolysis|May 3, 2014
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case reportSimona Roggero, Silvia Vullo, Gisella Volpe, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2012
Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic miceClaudia Casnici, Gisella Volpe, Katia Crotta, et al.
Annals of the New York Academy of Sciences|July 4, 2002
From genes to therapy: the case of Philadelphia chromosome-positive leukemiasDaniela Cilloni, Aagelo Guerrasio, Emilia Giugliano, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy|July 14, 2017
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia PatientsClaudia Casnici, Katia Crotta, Gisella Volpe, et al.
Annals of the New York Academy of Sciences|January 15, 2005
Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemiaGiuseppe Saglio, Alessandro Morotti, Giovanna Mattioli, et al.
Hybridoma (2005)|June 29, 2011
Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteinsClaudia Casnici, Gisella Volpe, Katia Crotta, et al.
Cancer Medicine|May 12, 2016
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapyDaniela Gallo, Paolo Nicoli, Chiara Calabrese, et al.
Oncoscience|December 19, 2015
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemiaCristina Panuzzo, Gisella Volpe, Elisa Cibrario Rocchietti, et al.
Cancer Research|June 5, 2007
Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approachesGisella Volpe, Alessandro Cignetti, Cristina Panuzzo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Letters|July 26, 2008
Imatinib resistance in CMLGisella Volpe, Cristina Panuzzo, Stefano Ulisciani, et al.
Journal of Thrombosis and Thrombolysis|May 3, 2014
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case reportSimona Roggero, Silvia Vullo, Gisella Volpe, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2012
Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic miceClaudia Casnici, Gisella Volpe, Katia Crotta, et al.
Annals of the New York Academy of Sciences|July 4, 2002
From genes to therapy: the case of Philadelphia chromosome-positive leukemiasDaniela Cilloni, Aagelo Guerrasio, Emilia Giugliano, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy|July 14, 2017
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia PatientsClaudia Casnici, Katia Crotta, Gisella Volpe, et al.
Annals of the New York Academy of Sciences|January 15, 2005
Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemiaGiuseppe Saglio, Alessandro Morotti, Giovanna Mattioli, et al.
Hybridoma (2005)|June 29, 2011
Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteinsClaudia Casnici, Gisella Volpe, Katia Crotta, et al.
Cancer Medicine|May 12, 2016
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapyDaniela Gallo, Paolo Nicoli, Chiara Calabrese, et al.
Oncoscience|December 19, 2015
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemiaCristina Panuzzo, Gisella Volpe, Elisa Cibrario Rocchietti, et al.
Cancer Research|June 5, 2007
Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approachesGisella Volpe, Alessandro Cignetti, Cristina Panuzzo, et al.
Pageof 1